Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
102.9 USD | -0.29% | +0.08% | +2.09% |
29/04 | Wells Fargo Adjusts Cardinal Health Price Target to $94 From $96 | MT |
25/04 | US FDA sends warning to Cardinal Health for marketing unapproved devices | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.11 for the 2024 fiscal year.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.09% | 25.1B | C+ | ||
+15.79% | 71.39B | C+ | ||
-1.22% | 8.59B | C | ||
+7.95% | 8.19B | B | ||
-20.48% | 7.91B | B- | ||
+15.26% | 4.31B | B+ | ||
-1.24% | 3.93B | B- | ||
-3.02% | 3.86B | B | ||
+21.10% | 3.64B | C+ | ||
+7.96% | 3.29B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAH Stock
- Ratings Cardinal Health, Inc.